A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
← catalyst calendarNCT06660667 · readout in 272 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
66estimated
Sites
26
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-21 | actual | When the study began enrolling |
| Primary completion | 2027-05-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-related Macular Degeneration
Interventions
- Biological: SAR402663
- Drug: Diluent
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of ocular treatment emergent adverse event (TEAEs)
measured Day 1 to Week 52
Incidence and severity of ocular treatment emergent serious adverse event (TESAEs)
measured Day 1 to Week 52
Incidence and severity of non-ocular TEAEs
measured Day 1 to Week 52
Incidence and severity of non-ocular TESAEs
measured Day 1 to Week 52
Number of participants with any clinically significant changes in laboratory variables
measured Day 1 to Week 52
Number of participants with any clinically significant changes in vital signs
measured Day 1 to Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed